NasdaqCM - Delayed Quote USD

KALA BIO, Inc. (KALA)

6.30 +0.11 (+1.78%)
At close: April 26 at 4:00 PM EDT
6.75 +0.45 (+7.14%)
After hours: April 26 at 6:10 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
3,892.00
11,240.00
6,362.00
Cost of Revenue
--
--
2,560.00
4,097.00
3,173.00
Gross Profit
--
--
1,332.00
7,143.00
3,189.00
Operating Expense
34,328.00
34,328.00
82,688.00
116,576.00
99,420.00
Operating Income
-34,328.00
-34,328.00
-81,356.00
-109,433.00
-96,231.00
Net Non Operating Interest Income Expense
-3,103.00
-3,103.00
-6,602.00
-8,276.00
-8,096.00
Other Income Expense
-4,768.00
-4,768.00
43,136.00
-24,896.00
--
Pretax Income
-42,199.00
-42,199.00
-44,822.00
-142,605.00
-104,327.00
Net Income Common Stockholders
-42,199.00
-42,199.00
-44,822.00
-142,605.00
-104,327.00
Diluted NI Available to Com Stockholders
-42,199.00
-42,199.00
-44,822.00
-142,605.00
-104,327.00
Basic EPS
-17.35
--
-29.48
-108.32
-99.50
Diluted EPS
-17.35
--
-29.48
-108.32
-99.50
Basic Average Shares
2,432.01
--
1,520.61
1,316.50
1,047.55
Diluted Average Shares
2,432.01
--
1,520.61
1,316.50
1,047.55
Total Operating Income as Reported
-39,663.00
-39,663.00
-81,706.00
-130,245.00
-96,231.00
Total Expenses
34,328.00
34,328.00
85,248.00
120,673.00
102,593.00
Net Income from Continuing & Discontinued Operation
-42,199.00
-42,199.00
-44,822.00
-142,605.00
-104,327.00
Normalized Income
-41,689.00
-41,689.00
-88,884.00
-116,398.00
-104,327.00
Interest Income
2,711.00
2,711.00
664.00
104.00
493.00
Interest Expense
5,814.00
5,814.00
7,266.00
8,380.00
8,589.00
Net Interest Income
-3,103.00
-3,103.00
-6,602.00
-8,276.00
-8,096.00
EBIT
-36,385.00
-36,385.00
-37,556.00
-134,225.00
-95,738.00
EBITDA
-36,082.00
-36,082.00
-37,019.00
-133,250.00
-94,826.00
Reconciled Cost of Revenue
--
--
2,560.00
4,097.00
3,173.00
Reconciled Depreciation
303.00
303.00
537.00
975.00
912.00
Net Income from Continuing Operation Net Minority Interest
-42,199.00
-42,199.00
-44,822.00
-142,605.00
-104,327.00
Total Unusual Items Excluding Goodwill
-510.00
-510.00
44,062.00
-26,207.00
--
Total Unusual Items
-510.00
-510.00
44,062.00
-26,207.00
--
Normalized EBITDA
-35,572.00
-35,572.00
-81,081.00
-107,043.00
-94,826.00
12/31/2020 - 7/20/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ATNF 180 Life Sciences Corp.
1.8000
+4.05%
 
TENX Tenax Therapeutics, Inc.
3.4800
-0.85%
 
PALI Palisade Bio, Inc.
6.05
-2.89%
 
SPRO Spero Therapeutics, Inc.
1.4600
+2.10%
 
IMRN Immuron Limited
2.6400
+6.02%
 
OVID Ovid Therapeutics Inc.
3.1000
+3.68%
 
NERV Minerva Neurosciences, Inc.
2.4365
-0.55%
 
GLMD Galmed Pharmaceuticals Ltd.
0.3916
+0.90%
 
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
 
ETNB 89bio, Inc.
8.26
+0.12%